retatrutide autoimmune disease CAS 2381089-83-2 (Retatrutide) Retatrutide (LY3437943) | GCGR/GIPR/GLP-1R Agonist

Retatrutide Research Peptide (Lyophilised, HPLC 99%) 59.00

Ready to expand your practice

Semaglutide (GLP-1 agonist): approximately 15% weight loss at 2.4 mg weekly Tirzepatide (GLP-1 and GIP dual agonist): up to 20.9% weight loss at 15 mg weekly Retatrutide (triple agonist): up to 24.2% weight loss at 12 mg weekly All three share once-weekly subcutaneous injection administration Retatrutide's glucagon receptor activity drives additional energy expenditure Key Takeaways Retatrutide is administered once weekly by subcutaneous injection, with Phase 2 trial doses ranging from 2 mg to 12 mg per week The 12 mg weekly maintenance dose produced the greatest average weight loss of 24.2% over 48 weeks in clinical trials Dosing always begins at a low starting dose (2 mg weekly) and escalates gradually over 16 to 24 weeks to minimise gastrointestinal side effects Retatrutide is not currently approved by the MHRA and is not available as a prescribed medication in the UK as of 2026 For those seeking treatment now, clinically approved weekly injectables such as semaglutide and tirzepatide are available through regulated prescribers When to Seek Professional Advice If you are considering retatrutide or any other injectable weight loss medication, speaking with a qualified prescribing pharmacist or doctor is essential before making any decisions

Some people notice changes within the first few weeks, while others experience more gradual progress over several months